CN114599394A - 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法 - Google Patents

用于在低蛋白浓度下使蛋白损失最小化的组合物和方法 Download PDF

Info

Publication number
CN114599394A
CN114599394A CN202080074309.9A CN202080074309A CN114599394A CN 114599394 A CN114599394 A CN 114599394A CN 202080074309 A CN202080074309 A CN 202080074309A CN 114599394 A CN114599394 A CN 114599394A
Authority
CN
China
Prior art keywords
gly
ser
thr
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080074309.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·朱
D·G·格林尼
Q·郝
S·肯纳普拉姆
M·J·特雷乌海特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN114599394A publication Critical patent/CN114599394A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CN202080074309.9A 2019-10-25 2020-10-23 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法 Pending CN114599394A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926089P 2019-10-25 2019-10-25
US62/926,089 2019-10-25
PCT/US2020/057065 WO2021081326A1 (en) 2019-10-25 2020-10-23 Compositions and methods for minimizing protein loss at low protein concentrations

Publications (1)

Publication Number Publication Date
CN114599394A true CN114599394A (zh) 2022-06-07

Family

ID=75620878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074309.9A Pending CN114599394A (zh) 2019-10-25 2020-10-23 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法

Country Status (12)

Country Link
US (1) US20220378908A1 (cg-RX-API-DMAC10.html)
EP (1) EP4048310A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022553058A (cg-RX-API-DMAC10.html)
KR (1) KR20220099585A (cg-RX-API-DMAC10.html)
CN (1) CN114599394A (cg-RX-API-DMAC10.html)
AU (1) AU2020370372A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022007776A2 (cg-RX-API-DMAC10.html)
CA (1) CA3155125A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022001035A1 (cg-RX-API-DMAC10.html)
IL (1) IL292211A (cg-RX-API-DMAC10.html)
MX (1) MX2022004944A (cg-RX-API-DMAC10.html)
WO (1) WO2021081326A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
JP7548475B1 (ja) * 2023-03-16 2024-09-10 小野薬品工業株式会社 抗体製剤
TW202517293A (zh) * 2023-07-07 2025-05-01 美商再生元醫藥公司 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物
CN120271709B (zh) * 2025-04-08 2026-03-31 康立泰生物医药(青岛)有限公司 一种抗cldn18.2纳米抗体及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169742A1 (en) * 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
CN105073136A (zh) * 2013-03-15 2015-11-18 葛兰素史克知识产权第二有限公司 低浓度抗体制剂
US20150335706A1 (en) * 2012-11-06 2015-11-26 Bayer Pharma Aktiengesellschaft Formulation for bispecific t-cell engagers (bites)
US20170218077A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
CN109562065A (zh) * 2016-06-07 2019-04-02 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
US20190099489A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. Novel Formulations Which Stabilize Low Dose Antibody Compositions
US20190151448A1 (en) * 2017-05-05 2019-05-23 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CN110088137A (zh) * 2016-10-19 2019-08-02 诺瓦罗技科斯生物科技有限公司 针对mica和micb蛋白的抗体
WO2019169245A1 (en) * 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
CN103387723A (zh) * 2013-07-31 2013-11-13 朱煜 一种不含dehp的聚氯乙烯材料及输液器
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335706A1 (en) * 2012-11-06 2015-11-26 Bayer Pharma Aktiengesellschaft Formulation for bispecific t-cell engagers (bites)
CN105073136A (zh) * 2013-03-15 2015-11-18 葛兰素史克知识产权第二有限公司 低浓度抗体制剂
WO2015169742A1 (en) * 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
US20170218077A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
CN109562065A (zh) * 2016-06-07 2019-04-02 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN110088137A (zh) * 2016-10-19 2019-08-02 诺瓦罗技科斯生物科技有限公司 针对mica和micb蛋白的抗体
US20190151448A1 (en) * 2017-05-05 2019-05-23 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US20190099489A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. Novel Formulations Which Stabilize Low Dose Antibody Compositions
WO2019169245A1 (en) * 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same

Also Published As

Publication number Publication date
US20220378908A1 (en) 2022-12-01
JP2022553058A (ja) 2022-12-21
KR20220099585A (ko) 2022-07-13
CL2022001035A1 (es) 2023-01-27
MX2022004944A (es) 2022-05-16
CA3155125A1 (en) 2021-04-29
EP4048310A1 (en) 2022-08-31
AU2020370372A1 (en) 2022-05-12
IL292211A (en) 2022-06-01
JP2026003626A (ja) 2026-01-13
WO2021081326A1 (en) 2021-04-29
EP4048310A4 (en) 2024-03-13
BR112022007776A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
US11987623B2 (en) Stabilized antibody compositions
JP2026003626A (ja) 低タンパク質濃度のタンパク質損失を最小限に抑えるための組成物及び方法
AU2019351715C1 (en) Methods for reducing aggregation of bispecific antibodies
CN101466404A (zh) 抗-egfr抗体的冻干制剂
JP2022500386A (ja) Ｃｓｆ−１ｒ抗体製剤
WO2017149513A1 (en) Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) Anti-mcam antibodies and associated methods of use
KR20150082328A (ko) 이중특이성 t-세포 연계체(bites)의 제제
US20230348596A1 (en) Pharmaceutical formulation
JP2026047374A (ja) 医薬製剤
CN116725961A (zh) 抗cd39抗体药物组合物及其用途
EA052968B1 (ru) Композиции и способы для минимизации потери белка при низких концентрациях белка
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
CN116529263A (zh) 包含bite双特异性抗体和甲硫氨酸的药物配制品
EA052508B1 (ru) Фармацевтический состав, содержащий биспецифичное антитело bite и метионин
CN116510006A (zh) 抗trbv9抗体的药物组合物及其用途
EA048312B1 (ru) Способы снижения агрегации биспецифических антител

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination